ALK and non-small cell lung carcinoma: Monotherapy ICIs represent groundbreaking front-line treatment options for EGFR/ALK/ROS1 non-mutant non-small cell lung cancer (NSCLC) with high PDL1 expression (≥50% expression) [4,5,6,7].